Not likely; ADD is a cash cow for Abbott - I remember 15 years ago GE tried to buy ADD (and that was when ADD was doing poorly) and Abbott did not sell.
TFS is a GE type ponzi scheme of a company - no divisions make profits, so they buy 'strategic fit' businesses and drive up stock price - heading for the inevitable collapse. Abbott is a 200 year old healthcare company - they will never sell to a bucket of bolts like TFS
Ill informed comment; GE pulled out with less than a weeks notice when it became apparent to GE that the integration costs of the acquisition was going to be much higher than planned; that week we were still splitting out shared service roles in finance, customer service and admin, as we were loading GE software onto servers and splitting the car park and making sure the diagnostics and POC were all on one floor while rapidly trying to find the ADC guys new office space. and putting a marquee up for the big "day one at GE" event So yes, Abbott did not sell, but because GE backed out at the last stages.... And yes, I was there.
They announced this week that the Core Instrument business (IA) would be moved to LC8...and would be a completely separate business from Transfusion products. Not sure what it means. Could this be a nice, tidy package for a potential sale? Who knows.
Perhaps; but word on wall street was that MIles felt he could get a better deal by growing ADD; bottom line was GE reduced Abbott's net take upon due diligence and Miles backed off
But ADD has failed to grow by market standards, only by internal measures. ADD continues to languish behind Roche & Siemens and is consistently behind both market growth and market share in every major market. It's a zombie ... I genuinely feel sorry for those remaining in that division, because the constant marketing refreshes and rehashes of the product offering mean nothing to the users in the market. Only when the last of the generation that made its money on Axsym finally retire and take their entrenched arrogant attitudes with them will the company start to understand the need for 21st century strategies for 21st century growth.
ADD is truly Abbott's old guard - Miles was President of ADD before becoming CEO of Abbott. ADD VPs are mostly ancient, only know Abbott culture, and have minimal external experience. ADD's stagnation is the direct result of such leaders' lack of innovative drive. Bring in outside leadership and ADD can thrive - provided the old guard let that person survive long enough.
If you spend any time at ADD HQ, you can feel the tenured old guard draining the life out of the business - average VP tenure there is over 25 Abbott years; you can't have innovative energy in that stale environment
